Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
| Autor: | Rewerska, Barbara, Sher, Lawrence D., Alpizar, Sady, Pauser, Sylvia, Pulka, Grazyna, Mozaffarian, Neelufar, Salhi, Yacine, Martinet, Camille, Jabert, Wafaa, Gudi, Girish, CA, Vinu, GN, Sunitha, Macoin, Julie, Anstett, Victor, Turrini, Riccardo, Doucey, Marie-Agnès, Blein, Stanislas, Konto, Cyril, Machkova, Martina |
|---|---|
| Zdroj: | In Journal of Allergy and Clinical Immunology: Global February 2024 3(1) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|